Skip to main content
$2.5 million CSL Centenary Fellowships awarded
  • Faster treatments for future pandemics (Brisbane)
  • Investigating the DNA factory in our bodies that makes everything (Melbourne)

MELBOURNE and BRISBANEOctober 27, 2021: Two Australian scientists have each been awarded a CSL Centenary Fellowship of $1.25 million over five years to undertake research that will transform our response to pandemics, and lead to new cancer treatments.

The Fellowships were presented at the Australian Academy of Health and Medical Sciences Annual Meeting 2021 on Wednesday 27 October.

Associate Professor Daniel Watterson, at The University of Queensland, will use his CSL Centenary Fellowship to identify and manufacture anti-viral antibodies and deliver them to patients using mRNA.

He is one of the inventors of the molecular clamp technology that holds a virus spike protein in its original form so it can generate an immune response in a vaccine. It was used to develop a potential Australian COVID-19 vaccine last year and is now being refined with a view to reducing vaccine development time to a few months.

Associate Professor Watterson believes molecular clamps can also enable rapid development of anti-viral drugs.

Dr Stephin Vervoort will use his CSL Centenary Fellowship to unravel fundamental steps in DNA transcription and use that knowledge to identify possible small molecule drugs that could target acute myeloid leukaemia (AML) and other cancers.

He is solving mysteries in the processes that enable the production of proteins from genes. The enzyme RNA polymerase II plays a critical role in transcribing DNA into mRNA. When this molecular machine makes mistakes, the consequences in humans can be profound and include, for example, the development of poor-prognosis cancers.

Dr Vervoort is based in Melbourne at WEHI and the Peter MacCallum Cancer Centre.

“Associate Professor Watterson and Dr Vervoort will both be generating fundamental knowledge that could transform how we fight disease,” said CSL Chief Scientific Officer Dr Andrew Nash.

“Our collective requirement for a rapid, worldwide response to COVID-19 has shown what medical research can achieve. It’s also shown that we have much to learn. Daniel and Stephin are both advancing fundamental human knowledge, but with potential practical applications for future pandemics and for cancer,” he said.

“It is this long-term purpose that the CSL Centenary Fellowships aim to support, by providing funding stability for leading mid-career Australian researchers and delivering on our promise to foster a thriving medical research community.”

### - ENDS - ### 

About the CSL Centenary Fellowships
The Fellowships are competitively selected, high-value grants available to mid-career Australians who wish to continue a career in medical research in Australia.

They are open to medical researchers working on discovery or translational research with a focus on rare/serious diseases, immunology or inflammation and are overseen by a selection committee comprising three independent members and two CSL representatives. The 2022 committee was chaired by Professor Sharon Lewin.

The Fellowships were established to mark 100 years since the establishment of CSL in 1916. Two individual, five-year, A$1.25 million fellowships are awarded each calendar year.

For further information, visit

About CSL

CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

For more information visit              

Get our latest news releases in your inbox
* Required Fields